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Human pluripotent stem cell (hPSC)-derived endothelial lineage cells constitutes a promising source for thera-
peutic revascularization, but progress in this arena has been hampered by a lack of clinically-scalable differentia-
tion protocols and inefficient formation of a functional vessel network integrating with the host circulation upon 
transplantation. Using a human embryonic stem cell reporter cell line, where green fluorescent protein expression is 
driven by an endothelial cell-specific VE-cadherin (VEC) promoter, we screened for > 60 bioactive small molecules 
that would promote endothelial differentiation, and found that administration of BMP4 and a GSK-3β inhibitor in 
an early phase and treatment with VEGF-A and inhibition of the Notch signaling pathway in a later phase led to ef-
ficient differentiation of hPSCs to the endothelial lineage within six days. This sequential approach generated > 50% 
conversion of hPSCs to endothelial cells (ECs), specifically VEC
+CD31
+CD34
+CD14
−KDR
high endothelial progenitors 
(EPs) that exhibited higher angiogenic and clonogenic proliferation potential among endothelial lineage cells. Phar-
maceutical inhibition or genetical knockdown of Notch signaling, in combination with VEGF-A treatment, resulted 
in efficient formation of EPs via KDR
+ mesodermal precursors and blockade of the conversion of EPs to mature ECs. 
The generated EPs successfully formed functional capillary vessels in vivo with anastomosis to the host vessels when 
transplanted into immunocompromised mice. Manipulation of this VEGF-A-Notch signaling circuit in our protocol 
leads to rapid large-scale production of the hPSC-derived EPs by 12- to 20-fold vs current methods, which may serve 
as an attractive cell population for regenerative vascularization with superior vessel forming capability compared to 
mature ECs.
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ORIGINAL ARTICLE
Introduction
Therapeutic vascularization through transplantation 
of endothelial lineage cells constitutes a conceptually 
attractive treatment for solid organs with pathology af-
fecting the local circulation, such as the ischemic heart 
[1, 2]. Human embryonic stem cells (hESCs) and human 
inducible pluripotent stem cells (hiPSCs), collectively 
referred to as human pluripotent stem cells (hPSCs), can 
be expanded indefinitely and have the potential to dif-
ferentiate to virtually any cell type in the human body 
[3, 4], thereby offering a plentiful source of cells for 
cell-based therapy approaches, including vascularization 
using endothelial cells (ECs) [2, 5]. However, a critical 
and frequently overlooked problem is the challenge of 
obtaining a sufficient number of cells for transplantation www.cell-research.com | Cell Research
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[2, 5-9]. Differentiation protocols permitting isolation 
of a cell type of interest with high purity and yield are 
often not available, and the desired cell type is generally 
a terminally differentiated cell with low capacity for pro-
liferation. There is growing appreciation in the field that 
isolation and expansion of committed progenitor cells, 
characterized by a restriction in developmental potential 
and a high proliferative rate, offers a potential remedy 
to these challenges. Previous reports, including from 
our laboratory, have documented the validity of this ap-
proach for the heart [10] and endocrine pancreatic [11] 
cell lineages. In the present study, we have extended this 
concept to cells of the endothelial lineage. We present a 
differentiation protocol resulting in rapid and efficient 
differentiation of hPSCs to the endothelial lineage, and 
have isolated and purified endothelial progenitors (EPs), 
a committed progenitor population within this lineage 
[12-14]. Moreover, we have identified the key molecular 
mechanisms controlling the balance between mainte-
nance of progenitor identity and further differentiation 
and maturation along the EC lineage.
We performed a screen in an effort to optimize dif-
ferentiation of hPSCs into endothelial lineage cells, with 
a focus specifically on identifying an EP population. By 
screening > 60 bioactive molecules, we identified two 
distinct phases during differentiation of hPSCs to the 
endothelial lineage. Priming cultures in the early phase 
with bone morphogenic protein (BMP) 4 and a glycogen 
synthase kinase-3β inhibitor (GSK-3βI), and EP induc-
tion in a later phase with vascular endothelial growth 
factor (VEGF)-A and pharmacological suppression of 
the Notch signaling pathway by the γ-secretase inhibitor 
DAPT, synergistically enhanced hPSC differentiation into 
EPs, defined as VE-cadherin (VEC)
+CD31
+CD34
+CD14
− 
cells. This cellular population exhibited the highest 
angiogenic and proliferative potential in clonal assays 
among the generated endothelial lineage cells, and fur-
ther transcriptional analyses identified them as a popula-
tion exhibiting an EP-specific molecular profile such as 
KDR
highId1
highNeuropilin
high, which was similar to that of 
human umbilical cord blood cells (HUCBCs) [12-14]. 
Mechanistic analyses revealed that BMP4 with GSK-3βI 
enhanced KDR promoter activity and thereby the induc-
tion of KDR
+ mesodermal precursors. VEGF-A was 
identified as an essential factor for endothelial differenti-
ation from such KDR
+ mesodermal precursors; however, 
VEGF-A alone also promoted EP (VEC
+KDR
highCD34
+) 
differentiation into mature ECs (VEC
+KDR
lowCD34
−), 
or KDR
+ precursor differentiation into non-endothelial 
lineage cells, e.g., smooth muscle cells (SMCs), which 
was enhanced especially in cultures with active delta-like 
4 (Dll4)/Notch signaling. In contrast, inhibition of Notch 
signaling by DAPT or genetic knockdown of core com-
ponents of the pathway using shRNA maintained high 
levels of KDR promoter activity, thereby promoting EP 
proliferation and blocking further differentiation to ma-
ture ECs. Therefore, our study showed that the combined 
use of DAPT with VEGF-A in a late phase promotes the 
efficient generation and proliferation of KDR
+ precursor-
derived EPs. 
Using this sequential approach (priming with BMP4 
and GSK-3βI, induction with VEGF-A and DAPT), hPSC-
derived EPs could be generated in only 6 days with around 
50% efficiency. hPSC-derived EPs successfully formed 
functional capillary vessel networks with anastomoses to 
host vessels in vivo after engraftment into immunocom-
promised mice, and also improved heart function in mice 
after myocardial infarction (MI). To our knowledge, this 
is the first description of a quick and efficient method for 
large-scale production of hPSC-derived EPs, and such 
cells are a promising cellular source for therapeutic re-
vascularization in ischemic cardiovascular diseases and 
in drug screening for compounds facilitating therapeutic 
angiogenesis and vasculogenesis.
Results
Transgenic hESC reporter cell line for monitoring of en-
dothelial differentiation
We established a transgenic reporter hESC line for 
convenient monitoring of differentiation to the endothe-
lial lineage. A 2.5-kilobase promoter sequence of the EC-
specific VEC (CDH5) gene [15, 16] was inserted into a 
lentiviral vector upstream of a cDNA sequence encoding 
enhanced green fluorescent protein (EGFP) (VEC-EGFP; 
Figure 1A). Lentiviral particles were produced and used 
to transduce human primary ECs, human primary fore-
skin fibroblasts, and human primary SMCs. Transduced 
ECs exhibited robust expression of EGFP, whereas no 
EGFP expression could be detected in transduced fi-
broblasts or SMCs (Supplementary information, Figure 
S1A-S1D). WA09 hESCs were transduced with VEC-
EGFP lentiviral particles and individual clones were 
selected and expanded. After spontaneous differentiation, 
six clonally expanded lines exhibited co-expression of 
EGFP and the pan-EC marker CD31 (or endogenous 
VEC) (Figure 1B, 1C and Supplementary informa-
tion, Figure S1E), and one hESC-VEC-EGFP reporter 
line was selected for subsequent experiments. hESC-
derived EGFP-expressing cells did not express alpha-
smooth muscle actin or vimentin, a marker of fibroblasts 
(Supplementary information, Figure S1F and S1G). The 
differentiated VEC-EGFP
+ cells sorted by fluorescence-
activated cell sorting (FACS) proliferated rapidly after Formation of human PSC-derived endothelial progenitors
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Figure 1 Establishment of a hESC reporter line for endothelial cell-specific lineage detection and the two modified protocols 
for endothelial differentiation. (A) A human VE-cadherin (VEC)-targeting construct. A 2.5-kb fragment of the human VE-cad-
herin promoter region [15, 16] was placed upstream of a cDNA encoding EGFP in a lentiviral expression vector (VEC-EGFP). 
(B, C) Spontaneously differentiating VEC-EGFP hESCs co-expressed EGFP (green) and the pan-endothelial cell marker 
CD31 (B; red), or endogenous VEC (C; red). BF, brightfield; Nuc, nuclei. Scale bars, 100 µm. (D) The VEC-EGFP
+ cells could 
successfully form capillary-like tube structures on Matrigel. Top, brightfield; bottom, VEC-EGFP. Scale bars, 50 µm (insets) 
and 200 µm. (E, F) Schematic diagrams of the two differentiation protocols. In method A (E), hESC-derived EBs were initially 
generated in suspension cultures with BMP4 (day 0-3; phase 1), and the EBs were transferred to adherent conditions on day 
3 and cultured with VEGF-A (day 3-7; phase 2). In method B (F), dissociated single hESCs were directly seeded on adherent 
conditions and stimulated with BMP4 (day 1-4; phase 1) in N2/B27 medium, and the medium was switched to StemPro-34 
medium containing VEGF-A on day 4 (day 4-6; phase 2). FACS analyses were performed to sort a VEC-EGFP
+CD31
+ endo-
thelial cell population on day 7 (method A; E) or day 6 (method B; F), and the sorted cells were expanded in endothelial cell 
conditions in phase 3 (~day 14). We tested the efficacies of > 60 bioactive molecules for effects on endothelial differentiation 
when they were administered in phase 1 (illustrated as “X”) or phase 2 (illustrated as “Y”) in addition to the basic protocol 
consisting of BMP4 in phase 1 and VEGF-A in phase 2. (G) Representative FACS results detecting the VEC-EGFP
+CD31
+ 
ECs at the end of phase 2 when the effective molecules for endothelial differentiation were used. (H) The combination of 
BMP4/GSK-3βI in phase 1 and VEGF-A/DAPT in phase 2 (left) with adjunctive PLGF and HGF in phase 2 (right) synergisti-
cally promoted endothelial differentiation and could generate VEC
+CD31
+ ECs with ~50% - 60% efficacy. (I, J) Averaged per-
cent EC (I) and sorted EC number (J) at the end of phase 2 in each treatment combination. *P < 0.01 and **P < 0.0001 vs 
Basic (BMP4+VEGF-A); ***P < 0.0001 vs Basic+DAPT or Basic+GSK-3βI. Error bars, SD (n ≥ 3).
replating (Supplementary information, Figure S1H) and 
formed capillary-like structures in vitro (Figure 1D). Im-
munocytochemistry revealed that VEC-EGFP
+ cells ex-
pressed the well-characterized EC markers CD31, VEC 
and von Willbrand factor (vWF) (Supplementary infor-
mation, Figure S1I). Taken together, these data document 
that the VEC promoter construct faithfully reports VEC 
expression, and that transgenic VEC-EGFP hESC lines 
express EGFP as they adopt the EC fate. 
Optimization of differentiation to the endothelial lineage
We used the transgenic VEC-EGFP reporter hESC line 
to optimize endothelial differentiation of hESCs. Differ-
entiation experiments were performed using two previ-
ously described protocols with minor modifications: one 
based on embryoid body (EB) formation in suspension 
culture (method A) [17], and the other based on mono-
layers of dissociated adherent single cells (method B) 
[18] (Figure 1E and 1F). Both protocols are comprised of 
three steps: mesodermal specification (phase 1), vascular 
commitment (phase 2), and EC expansion after sorting 
the VEC-EGFP
+ endothelial population using FACS 
(phase 3). We found treatment with BMP4 in phase 1 
and VEGF-A in phase 2 to be indispensable for endothe-
lial differentiation. No VEC
+CD31
+ ECs were detected 
when either of these factors was omitted. However, as 
previously reported [19-21], the efficiency of endothelial 
induction with BMP4/VEGF-A was only 1% - 3% of the 
total cell population on day 6-7, resulting in a low yield 
of ECs (Supplementary information, Figure S2A and 
S2B). Using a library of > 60 bioactive molecules, con-
sisting of growth factors, cytokines, and activators or in-
hibitors of signaling pathways (Supplementary informa-
tion, Table S1), we performed a screen to identify mol-
ecules that would enhance BMP4/VEGF-A-mediated en-
dothelial differentiation when administered during phase 
1 or 2 of differentiation (Figure 1E and 1F). Treatment 
with the GSK-3β inhibitors BIO (6-bromoindirubin-3′-
oxime; Sigma) or CP21R7 (Roche) in phase 1, resulting 
in activation of the canonical Wnt signaling pathway, and 
the γ-secretase inhibitor DAPT (Sigma) in phase 2, which 
inhibits the Notch signaling pathway, significantly pro-
moted hESC differentiation into VEC
+CD31
+ ECs on day 
6-7 (Figure 1G and Supplementary information, Figure 
S2C and S2D). Application of the TGFβ signaling inhibi-
tor SB431542 in phase 2 also enhanced hESC endothe-
lial differentiation, as previously reported [17]; however, 
the efficiency was much lower compared with GSK-3βI 
or DAPT treatment (Figure 1G). BMP4/VEGF-A treat-
ment combined with administration of GSK-3I in phase 
1 and DAPT in phase 2 was found to enhance endothelial 
differentiation in a synergistic manner. VEC
+CD31
+ ECs 
constituted around 50% of the total cells and the yield 
of VEC
+CD31
+ ECs at the end of phase 2 was increased 
by 30-fold (Figure 1H-1J). In addition, treatment with 
placental growth factor (PLGF) and hepatocyte growth 
factor (HGF) in phase 2 further promoted endothelial 
differentiation (Figure 1H-1J and Supplementary infor-
mation, Figure S2E). We did not observe synergistic ef-
fects for endothelial differentiation through simultaneous 
treatment with SB431542 and either GSK-3I or DAPT. 
As shown in Supplementary information, Figure S2C 
and S2D, we found that monolayer-based differentiation 
resulted in more efficient endothelial differentiation and Formation of human PSC-derived endothelial progenitors
824
npg
 Cell Research | Vol 24 No 7 | July 2014
a higher yield of ECs than EB-based differentiation, and 
therefore all subsequent experiments were performed 
using the monolayer differentiation protocol. We also 
found that CP21R7 had more stable results unaffected 
by its lot number, compared to BIO, and therefore, we 
basically used CP21R7 as a GSK-3β inhibitor in phase 1 
in the following experiments. Experiments in additional 
hPSC lines verified that our monolayer differentiation 
protocol, consisting of BMP4/GSK-3βI administration in 
phase 1 and VEGF-A/DAPT administration in phase 2, 
resulted in robust endothelial differentiation with mini-
mal differences in efficiency between different cell lines 
that did not reach statistical significance (Supplementary 
information, Figure S2F).
BMP4 and a GSK-3β inhibitor enhances the induction of 
KDR
+ precursors prior to vascular commitment
During endothelial differentiation of hESCs, expres-
sion levels of KDR (also known as VEGFR2), a recep-
tor of VEGF-A and a key component of the signaling 
pathway that specifies EC precursors at their earliest 
stages of development [22-25], were monitored by flow 
cytometry. On day 0, cultures of undifferentiated hESCs 
exhibited partial and weak expression of KDR and ro-
bust expression of TRA-1-60, a marker of undifferenti-
ated hESC (Supplementary information, Figure S3A). 
During differentiation, KDR
+ expression levels initially 
decreased, but increased again on day 4 with stronger 
intensity after BMP4 treatment (Supplementary infor-
mation, Figure S3A and S3B), as previously reported 
[26, 27]. Intriguingly, the administration of GSK-3βI 
with BMP4 in phase 1 significantly increased the KDR
+ 
cell ratio on day 4 (Supplementary information, Figure 
S3C). Either VEC
+ or CD31
+ cells were not detected on 
day 4; however, they started to emerge with VEGF-A 
treatment on day 5 (Supplementary information, Figure 
S3B). To determine the relevance of KDR induction for 
endothelial differentiation, KDR
+ and KDR
− cells were 
sorted on day 4 and cultured separately with VEGF-A for 
4 days. Flow cytometry analysis revealed that ~60% of 
the KDR
+ cell population differentiated into VEC
+CD31
+ 
ECs, whereas only less than 1% of the KDR
− cell popu-
lation became ECs (Supplementary information, Figure 
S3D). In addition, there was a strong positive correlation 
between KDR
+ cell ratio on day 4 and VEC
+ cell ratio on 
day 6 (Supplementary information, Figure S3E). These 
data suggest that KDR
+ precursors are indispensable for 
endothelial differentiation of hPSCs and that GSK-3βI 
with BMP4 enhanced induction of KDR
+ precursors in 
phase 1 prior to vascular commitment, likely leading to 
more efficient endothelial differentiation by the follow-
ing treatment with VEGF-A in phase 2.
KDR
highCD34
+CD14
− subpopulation of VEC
+CD31
+ ECs 
exhibits characteristics of EPs
hESC-derived VEC
+ cells sorted on day 6 co-ex-
pressed CD31 and KDR, and the majority (60% - 75%) 
were also expressing CD34 (Figure 2A). The CD34 an-
tigen, a marker of human hematopoietic stem cells, has 
been reported to likely label an EP population in adult 
circulation [12-14, 28-31]. Furthermore, previous work 
has suggested further subdivision of CD34
+ EPs on the 
basis of expression of the monocytic marker CD14 [24, 
32, 33]. We hypothesized that there should be a similar 
EP population in the hPSC-derived endothelial lineage, 
and thereby classified VEC
+CD31
+ ECs on day 6 into 
three subpopulations by the presence or absence of CD34 
and CD14 for further analyses examining EP character-
istics of these subpopulations (Figure 2B). Before that, 
we confirmed mRNA expression of CD14 in only CD14
+ 
ECs sorted by FACS with RT-PCR, but not in CD14
− 
ECs (Figure 2C).
Among the three EC subpopulations, CD34
+CD14
− 
ECs showed the highest vascular tube formation potency 
in vitro, comparable to that of HUCBCs, which are 
known to include immature EPs to a higher degree (Fig-
ure 2D-2F) [12-14]. CD34
+CD14
− ECs also exhibited the 
highest proliferative activity (Figure 2G). In keeping with 
this, CD34
+CD14
− ECs generated the largest number of 
VEC
+CD31
+ ECs at the end of phase 3 (day 14), when 
each subpopulation was separately cultured (Figure 2H). 
To analyze molecular profiles of these EC subpopulations 
compared to HUCBCs and human umbilical vein ECs 
(HUVECs), PCR array analyses were performed focus-
ing on endothelial lineage-related genes (Figure 2I and 
2J). As shown in Figure 2I, endothelial lineage-enriched 
genes such as CD31 (PECAM1), endoglin (ENG), VEC 
(CDH5), and endothelial nitric oxide synthase (eNOS; 
also known as NOS3) were approximately equally ex-
pressed in all of these groups. Genes that exhibited high-
er expression levels in CD34
+CD14
− ECs than in CD34
−
CD14
− and CD14
+ ECs included KDR, Flt1 (VEGFR1), 
Id1, and Neuropilin (NRP), which have been reported as 
cell surface markers or transcriptional factors expressed 
in EPs [32-37]. As a result, CD34
+CD14
− ECs exhibited 
an expression profile similar to that of HUCBCs, while 
CD34
−CD14
− ECs had a profile relatively close to that of 
HUVECs. As expected, CD14
+ ECs showed inflamma-
tory phenotype, at least in part. We also analyzed molec-
ular profiles of CD34
+CD14
− EC-derived cells through 
several passages 30 and 60 days after initial FACS sort-
ing. Interestingly, CD34
+CD14
− EC-derived cells after 
several passages could hold the endothelial lineage phe-
notype, represented by expression of PECAM1, ENG, 
CDH5, and NOS3 [24, 32, 33], although expression of www.cell-research.com | Cell Research
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EP-related genes had already been decreased (Figure 2I 
and 2J). 
To further test the clonogenic proliferative potential 
of the three EC subpopulations in a rigorous manner, 
we developed a clonal single-cell culture assay (Figure 
3A). The percentage of single cells undergoing at least 
one cell division during 14 days was significantly higher 
in CD34
+CD14
− ECs (48.2% ± 6.3%) than in CD34
−Formation of human PSC-derived endothelial progenitors
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Figure 2 Subpopulation analyses of VEC
+CD31
+ ECs for identifying an endothelial progenitor population. (A) Expression 
of KDR and CD34 in the VEC
+CD31
+ ECs on day 6 was evaluated by FACS. (B) VEC
+CD31
+ ECs on day 6 were divided 
into three subpopulations (CD34
+CD14
−, CD34
−CD14
−, and CD14
+) for further characterization. (C) CD14 mRNA expres-
sion in CD14
+ and CD14
− populations sorted by FACS was analyzed with RT-PCR. (D) In vitro tube formation on Matrigel. 
Left, brightfield; right, EGFP. Scale bars, 100 µm. (E) High magnification photographs of tube formation in D (CD34
+CD14
− 
ECs). Arrows indicate the lumens of the tubes formed by implanted CD34
+CD14
− ECs. Top, brightfield; bottom, EGFP. Scale 
bars, 50 µm. (F) Quantitative results of total tube area in the tube formation assay. HUCBC, human umbilical cord blood cell; 
HUVEC, human umbilical vein endothelial cell. *P < 0.01. (G) The cell proliferation (MTS) assay showing the significant dif-
ference among the three subpopulations. *P < 0.01. (H) Generated VEC
+CD31
+ EC numbers on day 14 derived from 1 × 10
4 
cells of each EC subpopulation sorted on day 6. *P < 0.01. (I) Molecular profiles of the three EC subpopulations on day 6, 
non-EC (VEC
−CD31
−), HUCBC, HUVEC, and CD34
+CD14
− EC (EP)-derived cell 30 and 60 days after initial FACS sorting 
through several passages were analyzed using PCR arrays (SABiosciences), focusing on endothelial lineage-related genes. 
The clustergram image of array data shows differentially expressed genes among the populations. Red indicates increased 
expression, whereas green indicates decreased expression. (J) Quantitative comparisons of mRNA expression of the select-
ed genes in the PCR array data in I among the populations. (1) non-EC (VEC
−CD31
−); (2) CD14
+ EC; (3) CD34
−CD14
− EC; (4) 
CD34
+CD14
− EC (EP); (5) HUCBC; (6) HUVEC; (7 and 8) EP-derived cell 30 days and 60 days after sorting. *P < 0.05 and 
**P < 0.01 vs non-ECs. †P < 0.01 vs (2) and (3). #P < 0.01 and ##P < 0.0001 vs (3) and (4). Error bars, SD (n ≥ 3).
CD14
− (8.8% ± 1.8%) or CD14
+ ECs (15.4% ± 3.3%) 
(Figure 3B). The average number of cell progeny derived 
from single-plated CD34
+CD14
− ECs was 10- to 30-
fold greater than that from single-plated CD34
−CD14
− or 
CD14
+ ECs (Figure 3C and 3D). Approximately half of 
the CD34
+CD14
− ECs sorted on day 6 became negative 
for CD34 on day 14 and exhibited weaker expression of 
KDR when cultured with VEGF-A in phase 3 (Figure 
3E), presumably indicating EC maturation. 
Finally, to examine what percentage of cells would be 
putative hemogenic ECs, which are considered as inter-
mediately differentiated vascular ECs that generate he-
matopoietic cells during embryogenesis [38, 39], we ana-
lyzed the expression ratio of c-kit, which is considered 
as one of the important markers of hemogenic ECs and 
their progeny hematopoietic progenitor cells as well as 
endothelial markers [38, 39], in each EC subpopulation. 
We found that the CD14
+ EC subpopulation contained 
higher number of c-kit-positive cells (20.4% ± 3.3%), 
while the CD34
+CD14
− EC subpopulation contained 
much fewer number of c-kit-positive cells (0.9% ± 0.3%) 
(Supplementary information, Figure S4A-S4C), suggest-
ing that the coexistence of hemogenic ECs/hematopoietic 
progenitor cells among the CD34
+CD14
− EC subpopula-
tion was a rare event. Collectively, these data support the 
notion that hESC-derived VEC
+CD31
+CD34
+CD14
− cells 
contain a discriminative EP population, and thereafter, 
we named this population as human PSC-derived EP. 
The Notch signaling pathway inhibitor DAPT promotes 
EP proliferation and blocks its differentiation into ma-
ture EC
Next, we sought to determine whether Notch sig-
naling affects the differentiation and/or proliferation 
of KDR
+ precursors and EPs. First, we cultured the 
VEC
+CD31
+CD34
+CD14
− EPs sorted on day 6 with 
VEGF-A and recombinant human Dll4 (rhDll4) protein 
(a ligand of the Notch receptor) or the Notch signaling 
inhibitor DAPT in phase 3. The biological activity of 
rhDll4 and DAPT was evaluated by monitoring levels of 
active Notch1 (the Notch1 intracellular domain [N1ICD]) 
in nuclear extracts of cultured cells by immunoblotting 
(Figure 3F and 3G). Interestingly, combined treatment 
with VEGF-A and DAPT in phase 3 maintained a higher 
ratio of EPs (84%) among the cultured endothelial lin-
eage cells on day 14 compared to treatment with VEGF-
A alone (46%), whereas VEGF-A and rhDll4 decreased 
the ratio of EPs (28%) (P < 0.01) (Figure 3H). Simi-
larly, combined treatment with VEGF-A and DAPT in 
phase 2 enhanced the induction of VEC
+CD31
+ ECs, 
specifically CD34
+CD14
− EPs, whereas VEGF-A and 
rhDll4 decreased ratios of both VEC
+CD31
+ ECs and 
CD34
+CD14
− EPs among ECs (Figure 3I).
To gain insights into the molecular basis of how in-
hibition of Notch signaling promotes endothelial differ-
entiation, we monitored VEC and KDR expression after 
administration of VEGF-A and/or DAPT during phase 
2 of differentiation. DAPT significantly increased the 
ratio of KDR
+ cells on day 6, although treatment with 
DAPT alone only resulted in a few scattered VEC
+ cells 
(Supplementary information, Figure S5A). VEGF-A 
treatment in phase 2, after the priming with BMP4/GSK-
3βI, resulted in around 15% VEC
+ of the total number of 
cells, but the total KDR
+ cell ratio was lower in cultures 
treated with VEGF-A alone than with DAPT alone. In-
terestingly, the combined use of DAPT and VEGF-A in 
phase 2 resulted in a substantially higher ratio of VEC
+ 
cells, approaching 50%, along with a higher ratio of total 
KDR
+ cells (Supplementary information, Figure S5A). 
Taken together, simultaneous treatment with DAPT and www.cell-research.com | Cell Research
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VEGF-A resulted in a synergistic effect, suggesting that 
DAPT might enhance responsiveness of hESC-derived 
mesodermal precursors to VEGF-A for endothelial dif-
ferentiation through maintaining or activating KDR 
activity. This notion is supported by a growing body of 
evidence showing that VEGF-A/KDR signaling controls 
expression of the Notch ligand Dll4 in ECs as part of a 
negative feedback loop, where Dll4-mediated activation 
of Notch receptors results in repression of KDR tran-
scription [40-42]. Quantitative RT-PCR and immunoblot-
ting confirmed elevated levels of Dll4 mRNA and protein 
in differentiating hESCs treated with VEGF-A (Supple-
mentary information, Figure S5B and S5C) along with 
upregulation of the canonical Notch downstream target 
genes Hes1, Hey1, and Hey2 (Supplementary informa-
tion, Figure S5D-S5F). Notably, administration of DAPT 
together with VEGF-A did not affect the expression level 
of Dll4 compared to VEGF-A treatment alone, but sig-
nificantly attenuated VEGF-A-induced upregulation of 
Notch target gene expression (Supplementary informa-Formation of human PSC-derived endothelial progenitors
828
npg
 Cell Research | Vol 24 No 7 | July 2014
tion, Figure S5B-S5F).
Inhibition of Notch signaling in combination with VEGF-
A blocks KDR
+ mesodermal precursor differentiation 
into non-endothelial lineages
KDR
+ cells have previously been described as multi-
potent precursors during mesodermal development, with 
a potential to differentiate into not only ECs but also vas-
cular SMCs and cardiomyocytes [24, 25, 40]. To inves-
tigate the direct effects of DAPT on the developmental 
potential of KDR
+ precursors, we sorted hESC-derived 
KDR
+ cells on day 4 and cultured them under differenti-
ating conditions with rhDll4 or DAPT (Figure 4A). After 
4 days, VEGF-A treatment promoted endothelial dif-
ferentiation of KDR
+ precursors and decreased KDR ex-
pression, along with limited but detectable differentiation 
into vascular SMCs (PDGFRα- or smooth muscle myosin 
heavy chain (SM-MHC)-positive) and cardiomyocytes 
(cTnT-positive) (Figure 4A-4C). Combined treatment 
with rh-Dll4 and VEGF-A enhanced differentiation of 
KDR
+ precursors into vascular SMC and cardiomyocyte 
lineages, and attenuated endothelial differentiation (Fig-
ure 4A-4C), which is in keeping with previous reports 
[43, 44]. In contrast, treatment with DAPT and VEGF-A 
significantly enhanced the induction of ECs, with main-
tained KDR expression, while attenuating differentiation 
into SMCs and cardiomyocytes (Figure 4A-4C).
To investigate whether the findings obtained in the 
hESC-based endothelial differentiation system also 
would be applicable to human fetal heart-derived KDR
+ 
precursors, we collected the cardiac mesenchymal cell 
(CMC) fractions, including KDR
+ precursors, derived 
from human fetal hearts (9 weeks of gestation), as previ-
ously described [45]. Four to 6 days after culture with or 
without DAPT, FACS analyses, and immunocytochemi-
cal studies revealed that DAPT treatment significantly in-
creased the KDR
+ cell ratio/number compared to control 
(Figure 4D and 4E). These findings suggest that DAPT 
promotes proliferation and inhibits differentiation of ex 
vivo-cultured KDR
+ precursor cells from human fetal 
heart tissue. It also further corroborates the notion that 
DAPT treatment with VEGF-A induces and maintains 
EP (VEC
+CD31
+CD34
+CD14
−KDR
high) identity during 
hPSC endothelial differentiation through a two-pronged 
mechanism: VEGF-A/DAPT treatment instructs KDR
+ 
precursors to adopt the endothelial fate at the expense 
of non-endothelial lineages, and inhibits the negative 
VEGF-Notch feedback mechanism resulting in KDR 
downregulation and further maturation along the endo-
thelial lineage.
The canonical Notch signaling pathway attenuates KDR 
expression in EPs
Our studies showed that VEGF-A alone in phase 2 
induced differentiation of hESC-derived KDR
+ precur-
sors to the endothelial lineage, but also attenuated levels 
of KDR expression (Figure 4A), resulting in a lower 
ratio of VEC
+CD31
+CD34
+CD14
−KDR
high EPs among 
VEC
+CD31
+ ECs (Figure 3I). DAPT attenuated the 
VEGF-A-induced upregulation of Notch target gene ex-
pression (Supplementary information, Figure S5D-S5F), 
leading us to hypothesize that Notch signaling might 
mediate the effect of VEGF-A on KDR expression, and 
that DAPT might block the decrease of KDR expression 
through the downregulation of the Notch downstream 
targets.
Figure 3 The CD34
+CD14
− subpopulation among VEC
+CD31
+ ECs represents an endothelial progenitor population, and 
Notch signaling controls their proliferation or further maturation. (A) Schematic of the single-cell culture experiment. On day 
6 in the endothelial differentiation, the single cells of the three subpopulations (CD34
+CD14
−, CD34
−CD14
−, CD14
+) among 
hESC-derived VEC
+CD31
+ cells were sorted onto 96 well plates (1 cell/well) and cultured under endothelial cell conditions 
for 14 days. (B, C) Percent of single cells dividing (B), defined as undergoing ≥ 1 cell division, and the average number of 
cell progeny per well after 14 days (C) were measured in each EC subpopulation. *P < 0.0001 vs CD34
−CD14
− and CD14
+ 
EC. (D) Representative photomicrographs of the single CD34
−CD14
− (top), CD34
+CD14
− (middle), and CD14
+ EC (bottom) 
culture assay. Scale bars, 50 µm (day 0) and 100 µm (day 3, day 9 and day 14). Day 3, day 9 and day 14, brightfield; day 
0 and insets of day 14, VEC-EGFP. (E) Expression of CD34 and KDR on day 14 in the cultured cells derived from the EPs 
(VEC
+CD31
+CD34
+CD14
−) sorted on day 6. After sorting, EPs were cultured with VEGF-A and analyzed with FACS on day 
14. (F) Representative images of western blot analysis for active Notch1 (the Notch1 intracellular domain (N1ICD)) in nuclear 
extracts of the cultured cells treated with VEGF-A with or without rhDll4 or DAPT. (G) Quantitative results in F are shown. 
Bands were scanned and quantified with Image J. The signal intensity was normalized to β-actin expression. (−) indicates no 
molecules. *P < 0.05 vs (−), **P < 0.01 vs (−) and VEGF-A, #P < 0.01 vs VEGF-A, and VEGF-A + rhDll4. (H) Diverse ratios 
of VEC
+CD31
+CD34
+CD14
− cells among VEC
+CD31
+ cells on day 14. 1 × 10
4 VEC
+CD31
+CD34
+CD14
− cells (EPs) were sort-
ed on day 6 and cultured with VEGF-A with or without rhDll4 or DAPT in phase 3. Notably, combined treatment with VEGF-
A and DAPT maintained a higher ratio of VEC
+CD31
+CD34
+CD14
− cells among the cultured cells on day 14, whereas VEGF-
A and rhDll4 decreased that ratio (P < 0.01). (I) The differential EC (VEC
+CD31
+) and EP (CD34
+CD14
− EC) ratios on day 6 
induced with treatment with VEGF-A with or without rhDll4 or DAPT in phase 2. Error bars, SD (n ≥ 3).www.cell-research.com | Cell Research
Makoto Sahara et al.
829
npgFormation of human PSC-derived endothelial progenitors
830
npg
 Cell Research | Vol 24 No 7 | July 2014
To rigorously test this hypothesis and to gain further 
mechanistic insights into how Notch signaling regulates 
maturation of EPs highly expressing KDR, we generated 
pKDR-Luc, a KDR reporter vector where a human KDR 
promoter fragment (−900, +296) [23] controls expres-
sion of the firefly luciferase gene (Figure 5A). hESCs 
were transfected with pKDR-Luc in the undifferenti-
ated state, and 6 h after transfection, differentiation was 
initiated through treatment with BMP4 and/or GSK-3βI 
for 12 h (Figure 5B). We found that BMP4 treatment 
increased luciferase activity by fourfold compared with 
control (Figure 5C). Although GSK-3βI alone increased 
the KDR-luciferase activity only modestly, the combined 
administration of BMP4 and GSK-3βI increased lucifer-
ase activity by eightfold (Figure 5C). We then treated the 
cells with VEGF-A, rhDll4, and/or DAPT for additional 
18 h (Figure 5B). VEGF-A attenuated the BMP4-induced 
increase of KDR-reporter activity and in addition, rhDll4 
(with VEGF-A) further decreased luciferase activity 
(Figure 5C). Interestingly, DAPT blocked the VEGF-A-
induced decrease of KDR-reporter activity, maintaining 
luciferase activity at a high level (Figure 5C).
DAPT has been shown to function as a specific inhibi-
tor of γ-secretase [46], an enzymatic multi-subunit com-
plex catalyzing the liberation of the membrane-tethered 
NICD, the final step in ligand-mediated Notch receptor 
activation. Because Notch is not the only substrate of 
γ-secretase, we performed knockdown studies of core 
components of the Notch signaling pathway to validate 
that the effect of DAPT is due to its effects on Notch sig-
naling. Tetracycline-inducible shRNA lentiviral vectors, 
targeting Notch1, the DNA-binding protein RBP-Jκ that 
targets nuclear NICD to specific enhancers and promot-
ers of downstream target genes [47], and Notch signaling 
downstream targets Hes1 and Hey1 [48] were generated, 
and the corresponding virus particles were transduced 
into undifferentiated hESCs (Supplementary information, 
Figure S6A). First, we confirmed the tetracycline-induc-
ible knockdown effects for the expression of Notch1, 
RBP-Jκ, Hes1, and Hey1, respectively, by quantitative 
RT-PCR measured at 12-24 h after doxycycline (1 µg/
ml) administration (Supplementary information, Figure 
S6B). The inducible shRNA hESC lines were then differ-
entiated into endothelial lineage cells using the same pro-
tocol with or without doxycycline treatment from day 4 
(Figure 5D). As shown in Figure 5E and 5F, knockdown 
of Notch1 or RBP-Jκ induced by doxycycline in phase 
2 significantly promoted endothelial differentiation with 
the production of a higher number of CD34
+CD14
− EPs, 
compared with the case without doxycycline or control 
(non-targeting) shRNA-transduced hESCs. Similarly, 
genetic knockdown of Hes1 or Hey1 also promoted gen-
eration of EPs, although the effects were more modest 
compared to the effects of Notch1 and RBP-Jκ knock-
down (Figure 5G). Next, the undifferentiated inducible 
shRNA hESC lines were transfected with pKDR-Luc and 
after 6 h stimulated with BMP4 for the next 12 h. We 
then treated the cells with VEGF-A in the presence or ab-
sence of doxycycline (1 µg/ml) for additional 18 h (Figure 
5H). Thirty-six h after pKDR-Luc transfection, VEGF-A 
alone decreased the BMP4-induced KDR-luciferase ac-
tivity, whereas knockdown of Notch1 or RBP-Jκ blocked 
the VEGF-A-mediated decrease of KDR-reporter activity 
(Figure 5I). Furthermore, knockdown of Hes1 or Hey1 
also partially blocked the VEGF-A-mediated decrease 
of the KDR-luciferase activity (Figure 5I). These data 
strongly support the notion that treatment with VEGF-A 
in combination with DAPT or genetic knockdown of core 
components of the Notch signaling pathway in phase 2 
promotes hESC differentiation into CD34
+CD14
− EPs by 
maintaining KDR promoter activity via downregulation 
of the Notch downstream targets.
Transplanted hPSC-derived EPs form functional capil-
lary networks and anastomose with host vessels in vivo 
and improve heart function in mice after MI
Our finalized strategy for the production of hPSC-
derived EPs (VEC
+CD31
+CD34
+CD14
−) is illustrated 
Figure 4 DAPT enhances proliferation rather than differentiation of the KDR
+ precursors. (A) Differentiation of KDR
+ meso-
dermal precursors into the three cardiovascular lineages: endothelial cells (CD31
+), smooth muscle cells (PDGFRα
+) and 
cardiomyocytes (cTnT
+). KDR
+ precursors were harvested on day 4 and cultured with VEGF-A with or without rhDll4 or DAPT 
up to day 8 prior to FACS analyses. (B) Quantitative results of the PDGFRα- and cTnT-positive ratios at day 8 in each KDR
+-
derived population, differentially treated as in A. *P < 0.05 and **P < 0.01. Error bars, SD (n = 5). (C) Immunocytochemical 
images of KDR
+ precursor-derived smooth muscle cells (left) and cardiomyocytes (right). SM-MHC and cTnT signals are indi-
cated as red. DAPT attenuated VEGF-A-induced differentiation of KDR
+ precursors into smooth muscle cells and cardiomyo-
cytes (indicated as arrows, respectively). Green, VEC-EGFP; blue, nuclei. Insets, brightfield. Scale bars, 50 µm (cTnT) and 
100 µm (SM-MHC). (D) Expression of KDR in the human fetal heart (9 weeks of gestation)-derived cardiac mesenchymal cell 
fractions, treated with or without DAPT, was evaluated with FACS. (E) Immunocytochemical images of KDR
+ precursors in 
the human fetal heart-derived cardiac mesenchymal cell fractions. DAPT increased the number of KDR
+ precursors (red, ar-
rows). Blue, nuclei; top insets and bottom left, brightfield. Scale bars, 50 µm (bottom) and 100 µm (top). www.cell-research.com | Cell Research
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in Figure 6A and consists of a stepwise combination of 
treatment with: (1) BMP4 and GSK-3βI in phase 1 (day 
1-4); and (2) DAPT and VEGF-A with PLGF and HGF 
in phase 2 (day 4-6), using method B described above. 
With this simple approach, 2.5 million of EPs could be 
generated in only 6 days from 1 million of hPSCs (Fig-
ure 6B). When the 2.5 million of EPs were cultured with 
VEGF-A in phase 3, ~20 million VEC
+CD31
+ ECs were 
generated on day 14 (hPSC/EC ratio = 1:20) (Figure 6B). 
To test the vasculo/angiogenic effects in vivo, the hPSC-
derived EPs (≥ 1 million) were directly transplanted with 
Matrigel plugs subcutaneously into non-obese diabetic/
severe combined immunodeficiency (NOD/SCID) mice. 
Two weeks later, the transplanted EPs formed capil-
lary vessel networks in Matrigel plugs (Figure 6C), and 
those neo-vessels formed by transplanted VEC-EGFP
+ 
EPs exhibited functional anastomosis with host vessels 
of NOD/SCID mice (Figure 6D and 6E). This finding 
was supported by the evidence that VEC-EGFP
+ EPs co-
localized with lectin
+ cells (Figure 6F). The transplanted 
EP-derived neo-vessels continued to function for more 
than 3 months (Figure 6G). Quantification of the area 
of newly formed vessels revealed a correlation with the 
number of transplanted EPs (Figure 6H). Furthermore, 
a direct comparison between VEC
+CD31
+CD34
+CD14
− 
EPs harvested on day 6 of hPSC differentiation and 
VEC
+CD31
+ ECs harvested on day 14 of hPSC differen-
tiation or HUVECs revealed that grafted EPs exhibited 
an increased (three to fivefold) capacity to form vascular 
networks in vivo after grafting, compared to VEC
+CD31
+ 
ECs or HUVECs (Figure 6H). We did not see any tumor 
formation after transplantation of hPSC-derived EPs/
ECs.
Finally, to examine whether hPSC-derived EPs have 
the efficacy to promote vasculo/angiogenesis and to im-
prove the organ function in a mouse diseased model such 
as MI, we injected 1 × 10
7 EPs directly into ischemic 
(peri-infarct) regions of myocardium immediately after 
ligation of the left anterior descending coronary artery 
(LAD). Twenty-eight days after MI, the transplanted EPs 
significantly attenuated left ventricle (LV) remodeling, 
as determined by echocardiography measurement of LV 
end-diastolic diameter (LVEDD) and LV end-systolic 
diameter (LVESD), and thereby improved LV function, 
as determined by echocardiography measurement of 
fractional shortening (FS) (Supplementary information, 
Figure S7A and S7B). In histology, the EPs directly en-
grafted into microcirculation in ischemic myocardium 
and increased capillary density, which was derived from 
both the incorporation of EGFP
+ EPs into native vessels 
and the increased number of native vessel ECs (Supple-
mentary information, Figure S7C and S7D). We found 
that a subset of transplanted EP-derived vessels were 
covered with vascular SMCs (SM-MHC)
+, which is con-
sistent with mature vessels, in the peri-infarct regions of 
myocardium (Supplementary information, Figure S7E). 
Figure 5 DAPT or genetic knockdown of the Notch signaling pathway maintains KDR promoter activity through downregula-
tion of Notch signaling downstream targets. (A) A pKDR-Luc vector construct, containing the human KDR promoter fragment 
(−900, +296) [23] upstream of the firefly luciferase gene. (B) Schematic of the dual-luciferase assay experiments. Undifferen-
tiated hESCs were transfected with pKDR-Luc and pRL-SV40 (control) and after 6 h, stimulated with BMP4 and/or GSK-3βI 
for the next 12 h. Then, the cells were stimulated with VEGF-A, DAPT (with VEGF-A), or rhDll4 (with VEGF-A). 18 h and 36 h 
after the transfection, dual luciferase activities were measured with a luminometer. (C) The relative fold induction of firefly lu-
ciferase activity normalized to control Renilla luciferase activity was determined. *P < 0.01 vs control, **P < 0.0001 vs control, 
and P < 0.01 vs BMP4, †P < 0.05 vs BMP4, ‡P < 0.01 vs BMP4, #P < 0.01 vs VEGF. Error bars, SD (n ≥ 3). (D) Schematic of 
the endothelial differentiation experiments using the tetracycline (Tet)-inducible shRNA hESC lines. Undifferentiatied hESCs 
were initially transduced with Tet-inducible shRNA lentiviruses targeting a Notch signaling pathway (Notch1, RBP-Jκ, Hey1, 
and Hes1) and then differentiated into endothelial lineage cells using the same protocol with or without doxycycline treatment 
(1 µg/ml) from day 4. (E) Expression of RFP (a marker of cells expressing shRNA), VEC, CD34, and CD14 was evaluated 
with FACS on day 6 in endothelial differentiation of the Tet-inducible shRNA hESCs. Genetical knockdown of Notch1 induced 
by doxycycline (Dox) in phase 2 enhanced the production of both VEC
+ ECs and CD34
+CD14
− EPs among ECs compared to 
control (non-targeting shRNA-transduced hESCs). (F) Percent EP on day 6 in endothelial differentiation of the Tet-inducible 
shRNA hESCs. Genetic knockdown of Notch1 (left) or RBP-Jκ (right) promoted EP induction, compared to Scr (Scramble 
no-targeting ShRNA) and Dox (−). *P < 0.05 vs VEGF (−), **P < 0.0001 vs VEGF (−), †P < 0.0001 vs Scr and Dox (−). (G) 
Percent EP on day 6 of each Tet-inducible shRNA hESC line. Although the degree was modest, genetic knockdown of Hey1 
or Hes1 also promoted EP induction. *P < 0.0001 vs. VEGF (−), †P < 0.0001 vs. VEGF (+), ‡P < 0.01 vs. VEGF (+). (H) 
Schematic of the dual-luciferase assay experiments using the Tet-inducible shRNA hESCs. Tet-inducible shRNA hESC lines 
were transfected with pKDR-Luc and after 6 h, stimulated with BMP4 for 12 h, followed by the incubation with VEGF-A with 
or without Dox for additional 18 h. (I) Results of the dual-luciferase assay using the Tet-inducible shRNA hESCs. Similarly to 
DAPT, genetic knockdown of Notch1 or RBP-Jκ could maintain KDR promoter activity at a high level. Similarly, Hey1 or Hes1 
knockdown also resulted in higher luciferase levels than control shRNA. *P < 0.01 vs control, †P < 0.05 vs BMP4, ‡P < 0.01 
vs BMP4, ## P < 0.01 vs VEGF, #P < 0.05 vs VEGF. Error bars, SD (n ≥ 3).www.cell-research.com | Cell Research
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On the survival analysis up to day 45 after MI, the EP-
injected mice group revealed the better survival rate 
(64.3%), compared to control (vehicle) group (28.6%), 
although not statistically significant (n = 14, respectively; 
P = 0.09 by log-rank test) (Supplementary information, 
Figure S7F). 
These data provide direct experimental evidence that 
the EPs generated using the protocol described herein 
form functional vessel networks that anastomose with 
vessels of the host following transplantation with benefi-
cial outcomes, even in the diseased model. Moreover, our 
results suggest that EPs may constitute a better cellular 
vehicle for revascularization efforts than mature ECs.
Discussion
Ischemic cardiovascular disease is the leading cause of 
death worldwide, despite recent progress in therapeutic 
treatment [49]. Regenerative cellular therapy is a novel 
promising approach for therapeutic revascularization in 
ischemic cardiovascular disease [1, 2]. However, due to 
the limited regenerative capacity of mature vascular ECs 
[2, 5], generation of large numbers of vascular ECs will 
likely be required for sufficient contribution to the vascu-
lature to have clinical impact. In this regard, EPs derived 
from bone marrow and peripheral blood mononuclear 
cells have been investigated as a candidate cell popula-
tion to enhance ischemia-induced angio/vasculogenesis 
following ischemic cardiovascular disease [12-14]. How-
ever, the number of EPs existing in adult bone marrow 
and circulating blood is prohibitively low, and ampli-
fication of EPs is challenging [14, 28, 29]. In addition, 
the molecular signature of EPs has not been completely 
defined, except for partly accepted molecular marker 
specific to EPs [30, 31]. Thus, there have been few suc-
cessful studies where large numbers of EP-derived ECs 
with the capacity to form functional vessels following 
grafting could be obtained [50-52]. 
hPSCs exhibit multi-lineage potential and the ability 
to self-renew indefinitely [3, 4], and constitute a promis-
ing source for the production of endothelial lineage cells, 
including EPs and ECs. However, protocols for robust 
differentiation of hPSCs into large numbers of functional 
endothelial lineage cells have been elusive [6-9], largely 
due to an incomplete understanding of the specific devel-
opmental stimuli controlling the specification of meso-
dermal precursors into endothelial lineage cells [17, 53, 
54].
To date, the most successful approaches for directed 
differentiation of hPSCs into endothelial lineage cells 
(Supplementary information, Table S2) [6-9, 17, 18, 
54, 55] have relied on application of secreted extracel-
lular factors, primarily BMP4 and VEGF-A. In addition, 
James et al. [17] have reported that the TGFβ inhibitor 
SB431542 enhanced EC differentiation of hESCs when 
administered in combination with VEGF-A during days 
7-14 of differentiation, corresponding to endothelial 
commitment and expansion of differentiating cultures. 
However, in their report, administration of SB431542 
resulted in modest efficiency for CD31
+VEC
+ EC forma-
tion, corresponding to only a small minority (1.8%) of 
the total number of cells on day 14 of differentiation [17]. 
The total number of obtained ECs could be increased 
by sorting and expansion by another week of culture, 
Figure 6 Successful engraftment of generated hPSC-derived EPs to form functional vessels in vivo. (A) Schematic of our 
finalized approach for generation of hPSC-derived EPs (VEC
+CD31
+CD34
+CD14
−). This is comprised of phase 1 and 2 in 
only 6 days, and sequential application of the following molecules: BMP4/GSK-3βI in phase 1 and VEGF-A/DAPT in phase 
2. (B) Comparison of cell numbers of hPSCs before differentiation, generated EPs (day 6), and VEC
+CD31
+ ECs (day 14) 
after phase 3 expansion using our differentiation protocol. (C) Matrigel (MG) plugs with hPSC-derived EPs subcutaneously 
transplanted into NOD/SCID mice. In vivo live images of capillary vessel formation generated by the hPSC-derived VEC-
EGFP
+ EPs 2 weeks after transplantation. BF, bright field. Scale bars, 100 µm (bottom) and 200 µm (top). (D) The MG plug 
with hPSC-derived EPs were harvested 4 weeks after transplantation (top), fixed in 2% paraformaldehyde (bottom, left), and 
subjected to fluorescent whole-mount immunostaining. The bottom-right panel shows anastomosis (arrowhead) between 
the neovessel formed by transplanted EGFP
+ EPs and a host vessel of NOD/SCID mice expressing murine VE-cadherin 
(red). Scale bars, 500 µm (top) and 200 µm (bottom, right). (E) Fluorescent immunostaining of cryosections of the MG plug 
in D shows anastomoses (arrowheads) between the neovessel formed by transplanted EGFP
+ EPs and host capillary ves-
sels of NOD/SCID mice expressing murine VE-cadherin (red). Scale bar, 20 µm. (F) The neovessels formed by transplanted 
EGFP
+ EPs in a Matrigel plug with functional anastomosis (arrowhead) to native vessels were labeled with lectin (GS-IB4, 
blue). Scale bar, 20 µm. (G) In vivo live images of EGFP
+ EP-derived capillary vessels 3 months after transplantation. Black 
arrowheads indicate host angiogenic sprouting capillary vessels, whereas white arrowheads indicate neovessels formed by 
transplanted EPs in connection with host sprouting vessels. Scale bars, 100 µm. (H) The transplanted cell numbers of EPs 
(VEC
+CD31
+CD34
+CD14
−) sorted on day 6, ECs (VEC
+CD31
+) sorted on day 14 or VEC-EGFP
+ HUVECs were positively cor-
related with quantitative total tube area in in vivo Matrigel plugs. EPs have a three- to fivefold efficacy of quantitative vascular 
tube formation in vivo, compared with ECs or HUVECs. *P < 0.05 and **P < 0.01.www.cell-research.com | Cell Research
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resulting in a total yield of seven ECs from every hESC 
in the starting culture, and therefore, a total of 3 weeks 
of differentiation would be required to generate ECs of a 
sufficient number for revascularization purposes [2, 5]. 
Tatsumi et al. [18] have reported that activation of the 
Wnt signaling pathway by the GSK-3β inhibitor BIO as 
an initial priming step, combined with VEGF-A admin-
istration in a later phase, promoted hESC differentiation 
into VEC
+ cells to 20% of the total number of differen-
tiating cells on day 5. However, a net yield of ECs (0.2 
ECs from every hESC) in their approach was still mod-
est, and they did not show in vivo vessel formation by 
the generated ECs (Supplementary information, Table 
S2). In contrast, we find that controlled activation or in-
hibition of four extracellular ligand-receptor systems, the 
BMP, Wnt, VEGF, and Notch signaling pathways, en-
abled rapid and more efficient endothelial differentiation. 
Stepwise modulation of these signaling pathways signifi-
cantly promoted hPSC differentiation into endothelial 
lineage cells, specifically VEC
+CD31
+CD34
+CD14
− EPs, 
through KDR
+ mesodermal precursors. Our protocol 
results in ~50% of the cells being EPs after 6 days of 
differentiation, corresponding to a total yield of 2.5 EPs 
for every hPSC in the starting culture. Following further 
expansion for 8 days after sorting of EPs, corresponding 
to a total of 14 days of differentiation, the yield was 20 
VEC
+CD31
+ ECs for every hPSC in the initial culture, 
and this could be increased further by yet another week 
in culture to up to 140 ECs for every hPSC in the initial 
culture, indicating that purified EPs could be expanded 
without compromising their endothelial identity (Figure 
2I and 2J). Thus, our protocol represents a 12- to 20-fold 
improvement in the yield of ECs compared to previously 
published results (Supplementary information, Table S2). 
Importantly, the generated EPs on day 6 could be trans-
planted for revascularization; they rapidly and success-
fully formed functional vessels with anastomoses with 
the host circulation after transplantation in vivo with or 
without a diseased model (MI) (Figure 6 and Supplemen-
tary information, Figure S7), and maintained their endo-
thelial identity and functional properties with beneficial 
outcomes throughout the time line of our experiments (> 
3 months). Perhaps even more importantly, we provide 
direct experimental evidence that EPs exhibit markedly 
improved vessel formation compared to mature ECs ob-
tained at a later phase. Notably, this reduced the required 
time to obtain sufficient quantities of transplantable cells 
from hPSCs from 20 [17] to 6 days of differentiation. 
This is of not only experimental interest but also may 
be of importance for the field of regenerative medicine, 
since it has been suggested that shorter differentiation 
protocols may be beneficial for therapeutic applications 
[1, 2, 5].
An important aspect of our findings is the high-
efficiency generation of hPSC-derived EPs. Although a 
stringent definition and the molecular signature of EPs in 
adult circulation has been still a matter of debate [14, 51], 
it is generally agreed that they exhibit specific functional 
features, including capacity to form vessel-like structures 
that integrate with native vessels of immunocompro-
mised hosts in vivo, and significantly higher proliferative 
and clonogenic potential compared to mature ECs [12-
14, 28, 32, 33, 56-59]. To date, the existence of hPSC-
derived EPs has been less frequently investigated or 
debated; however, we hypothesized that there should be 
a similar EP population in the hPSC-derived endothelial 
lineage, and demonstrated that CD34
+CD14
− cells among 
the hPSC-derived endothelial lineage (VEC
+CD31
+) on 
day 6 of differentiation constitutes a discriminative EP 
population, because the VEC
+CD31
+CD34
+CD14
− cells 
exhibited the highest angiogenic, proliferative, and clo-
nogenic potential (Figures 2, 3 and 6), along with a char-
acteristic angiogenic molecular profile (Figure 2I and 2J), 
similar to HUCBCs that are considered to likely contain 
an EP population in adult circulation [5, 12-14, 32-37, 
56]. The differentiation potential of the hPSC-derived 
VEC
+CD31
+CD34
+CD14
−KDR
high EPs was exclusively 
restricted to mature, fully differentiated ECs, and formed 
functional capillaries in vivo. To our knowledge, this is 
the first report of better identification and purification of 
hPSC-derived EPs. 
Identifying molecules maintaining EPs in a prolifera-
tive state provided insights into the molecular circuitry 
controlling conversion of EPs to mature ECs. VEGF-A 
is a key angiogenic signal,
 and VEGF-A/KDR signal-
ing plays a central role in embryonic vasculogenesis and 
postnatal angiogenesis [25, 60]. We find that administra-
tion of VEGF-A leads to maturation of EPs, with con-
comitant lower levels of KDR protein. This appears to 
be mediated by upregulation of Dll4, a ligand for Notch 
receptors expressed in EPs. Dll4-mediated activation of 
Notch leads to downregulation of KDR expression, at 
least in part through direct effects of Notch target genes 
such as Hes1 and Hey1 on the KDR promoter, as previ-
ously shown in the HUVEC study [61]. Inhibition of 
Notch signaling, either by pharmacological treatment 
or shRNA-mediated knockdown of key components of 
the Notch signaling pathway, blocked the attenuation of 
KDR expression. This in turn maintained the responsive-
ness of EPs to VEGF-A and kept EPs in a proliferative 
state.
Notch signaling is an evolutionarily conserved path-
way originally identified in Drosophila melanogaster, 
where Notch receptor activation in a field of neural Formation of human PSC-derived endothelial progenitors
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progenitor cells maintains the undifferentiated state in a 
process known as lateral inhibition [62]. Notch signal-
ing has been dubbed “the gatekeeper of differentiation” 
in Drosophila neurogenesis, where Notch downstream 
target genes of the Hairy/Enhancer of Split family in-
hibits expression of proneural genes. However, a string 
of publications from mammalian systems have revealed 
that Notch signaling in some contexts also can promote 
differentiation, including development of the mammalian 
neural [63], hematopoietic [64], and vascular systems 
[65]. In cardiovascular development, Notch signaling has 
been implicated in numerous processes and differentia-
tion steps, including vascular smooth muscle differentia-
tion, arterial-venous cell fate decisions, proliferation of 
ECs and angiogenic growth of the blood vessel network 
[41, 43, 44, 66]. Between ECs, VEGF-A-induced Dll4/
Notch signaling restricts tip-cell formation and angio-
genic sprouting, possibly by repressing the expression 
of KDR in ECs, and genetic deletion or pharmacologi-
cal inhibition of Notch signaling enhanced angiogenic 
sprouting and increased EC proliferation in the retinal 
vasculature [41, 66]. We extend these findings by provid-
ing experimental evidence that VEGF-induced activation 
of the Notch signaling pathway attenuates KDR expres-
sion in KDR
+ mesodermal precursors and EPs, permits 
differentiation of KDR
+ precursors into non-endothelial 
lineages (vascular SMCs and cardiomyocytes), and pro-
motes maturation of EPs to mature ECs during hPSC 
differentiation. Conversely, inhibition of Notch signal-
ing results in maintained high levels of KDR expression 
in hPSC-derived KDR
+ precursors and EPs, thereby 
promoting proliferation at the expense of maturation 
along the EC lineage. Thus, in EPs, Notch signaling 
operates as a key mediator of a negative feedback loop 
that links VEGF activation with maturation to fully dif-
ferentiated ECs. By uncoupling VEGF stimulation and 
maturation, inhibition of the Notch pathway permits the 
stable culture and expansion of EPs, which is achieved 
mechanistically by alleviating Notch-induced repression 
of the KDR promoter. Taken together, this Notch-VEGF 
interaction provides the molecular basis for the efficient 
generation of EPs in our differentiation protocol (Supple-
mentary information, Figure S8A and S8B).
In summary, this study presents a new efficient ap-
proach to generate hPSC-derived EPs. Sequential 
modulation of four signaling pathways, characterized 
by BMP4/Wnt-mediated priming of pluripotent cells to 
early mesoderm, and EP induction and maintenance by 
VEGF-A administration in combination with inhibition 
of Notch signaling, promotes hPSC differentiation into 
EPs with significantly higher efficiency (≈ 50%) and in 
a shorter time (within 6 days) compared to previously 
published protocols for endothelial differentiation from 
hESCs [6-9, 17, 18, 53-56]. Moreover, we did not detect 
any significant differences in the efficiency of endothelial 
differentiation between different hESC and hiPSC lines. 
Human PSC-derived EPs generate functional capillary 
networks when transplanted in vivo, and can be further 
expanded in vitro. Finally, our study provides data sup-
porting the notion that hPSC-derived EPs are a superior 
vehicle for therapeutical vascularization compared to 
more mature populations of ECs in vivo. EPs exhibited 
markedly improved vessel formation relative to mature 
ECs upon transplantation, and formed functional anas-
tomoses with the host circulation with better outcomes 
in a mouse MI model. Tumor formation, a potential 
concern when transplanting progenitor cell populations 
with proliferative capacity, was not detected upon graft-
ing of EPs. Conceptually, if patient-derived or allogeneic 
iPSCs are available, hiPSC-derived EPs generated by 
our approach might serve as useful therapeutic tools for 
even acute/subacute ischemic diseases, although further 
studies are needed. Taken together, our results provide 
novel insights into the cellular and molecular pathways 
regulating hPSC differentiation into EPs/ECs, which may 
be instrumental in developing novel therapeutic avenues 
of cellular regeneration for ischemic cardiovascular dis-
eases.
Material and Methods
Human PSC culture
The hESC cell lines HUES3 (Harvard University), WA07, and 
WA09 (both WiCell Research Institute), and hiPSCs [67] were 
used for this study. The use of these cell lines were approved by 
the Institutional Review Board (IRB) for human and animal re-
search at Massachusetts General Hospital (MGH), and funding 
covering the performed experiments was secured from approved 
non-federal funding resources. Human ESCs/iPSCs were main-
tained on irradiated mouse embryonic fibroblast (MEF) feeder 
cells in DMEM/F12 medium (Gibco) supplemented with 20% 
KnockOut Serum Replacement (KO-SR; Gibco/LifeTechnologies), 
2 mM L-glutamine (Gibco), 0.1 mM non-essential amino acids 
(Gibco), 0.1 mM 2-mercaptoethanol (Gibco), and 10 ng/ml basic 
FGF-2 (R&D). For feeder-free culture of hESCs/hiPSCs prior to 
endothelial differentiation, cells were passaged onto Matrigel (BD 
Bioscience) coated plates (0.3 mg/mL) and cultured in mTeSR-1 
medium (StemCell Technologies) according to instructions from 
the manufacturer. Human fibroblasts, 293FT cells and MEFs were 
maintained in DMEM containing 10% fetal bovine serum (FBS), 
2 mM L-glutamine, and 1 mM sodium pyruvate.
VEC-GFP hESC reporter line
A reporter cell line was constructed for monitoring differentia-
tion of pluripotent hESCs to the endothelial lineage. A 2.5-kilobase 
fragment (−2 486, +24) of the human VEC promoter region [15, 
16] was isolated and amplified from a bacterial artificial chromo-www.cell-research.com | Cell Research
Makoto Sahara et al.
837
npg
some (BAC) clone by PCR. The fragment was placed upstream of 
EGFP in a promoterless, pFUGW-based lentiviral vector to gener-
ate the lentiviral hVEC-EGFP reporter vector. 293FT cells were 
transfected with hVEC-EGFP along with standard packaging vec-
tors. Viral supernatants were collected in three consecutive days 
72 h after transfection, concentrated by ultracentrifugation, and 
used to transduce undifferentiated WA09 hESCs. After selection 
using antibiotic resistance, the transduced hESCs were picked for 
isolation and expanded to confirm the viral incorporation by PCR. 
After expansion, these hVEC-EGFP reporter hESCs were differen-
tiated and screened for the presence of cells with co-expression of 
EGFP and the pan-EC marker PECAM-1 (CD31) or endogenous 
VEC.
Vascular endothelial differentiation protocols
Prior to differentiation to the endothelial lineage, hVEC-EGFP 
hESCs were grown to confluence on Matrigel-coated plate in 
mTeSR-1 medium as described above. Endothelial differentiation 
was achieved through modification of two previously described 
basal protocols [17-21]; one based on the generation of EB forma-
tion (method A), and the other using dissociated adherent single 
cells without EB formation (method B) (Figure 1E and 1F). Using 
these two protocols, we screened for > 60 bioactive small mol-
ecules (Supplementary information, Table S1) that would promote 
endothelial differentiation. The molecules were purchased from 
Peprotech, unless the vendor is specified. In method A, confluent 
hVEC-EGFP hESCs were incubated in 0.5 mg/ml dispase (Gibco) 
at 37 °C until colonies were completely detached from the sub-
strate. Human ESC-derived EBs were then cultured on ultra-low 
cluster plates (Costar) in hESC differentiation medium (DMEM/
F12 containing 2% KO-SR, 2 mM L-glutamine, 0.1 mM non-
essential amino acids, and 0.1 mM 2-mercaptoethanol), supple-
mented with 20 ng/ml BMP4 (R&D Systems), at 37 °C with 5% 
CO2 (day 0-3; phase 1). On day 3, EBs are transferred to adherent 
conditions on Matrigel-coated plates and cultured with 50 ng/
ml VEGF (Peprotech) (day 3-7; phase 2). Medium was replaced 
every other day. In the method B, confluent hVEC-EGFP hESCs 
were dissociated to single cells using Accutase (Gibco). hESCs 
were thereafter seeded onto Matrigel-coated plates and cultured 
in mTeSR-1 medium with 10 ng/ml of a Rock inhibitor (R&D) 
for 1 day. On the next day, medium was changed to DMEM/F12 
medium (Gibco) supplemented with N2 and B27 (N2/B27 me-
dium) (Invitrogen) containing 20 ng/ml BMP4, and the cells were 
cultured in these conditions for 3 days (day 1-4; phase 1). On day 
4, medium was switched to StemPro-34 serum-free medium (Invi-
trogen) containing 50 ng/ml VEGF, and the cells were cultured for 
2 days (day 4-6; phase 2). On day 7 (method A) or day 6 (method 
B), adherent differentiated cells were collected and analyzed by 
FACS. The sorted VEC (EGFP)
+CD31
+ endothelial lineage cells 
were then seeded onto fibronectin (Sigma)-coated plates in endo-
thelial basal medium-2 (EBM-2; Lonza) containing 8 ng/ml FGF-
2 and 50 ng/ml VEGF and expanded until day 14 (phase 3). 
FACS analysis and sorting
Adherent cells were collected from differentiating cultures 
using 0.25% trypsin-EDTA and analyzed by FACS (FACSAria; 
Beckton Dickinson) for detecting the expression of various specif-
ic cell surface markers and EGFP expression driven by the lentivi-
ral VEC reporter and for the isolation of endothelial lineage cells. 
We used mouse monoclonal fluorochrome-conjugated antibodies 
against the following human antigens: CD31, VEC, CD14, CD34, 
KDR, c-kit (BD Bioscience or eBioscience), tumor-related antigen 
(TRA)-1-60 (Millipore), platelet-derived growth factor receptor α 
(PDGFRα; BioLegend), and cardiac troponin T (cTnT; Abcam). 
FACS data were analyzed with FlowJo software (Treestart).
Immunocytochemistry
Cultured adherent cells were fixed with 4% paraformaldehyde 
and subjected to  immunocytochemistry using standard protocols 
and the following primary antibodies: anti-CD31 (mouse mono-
clonal, Cell Signaling Technology), anti-VEC (goat polyclonal, 
R&D), anti-vWF (rabbit polyclonal, Abcam), anti-smooth muscle 
myosin heavy chain (rabbit polyclonal, Biomedical Technologies 
Inc.), anti-α-smooth muscle actin (mouse monoclonal, Sigma), 
anti-cTnT (rabbit polyclonal antibody, Abcam), anti-vimentin (rat 
polyclonal, R&D), and anti-KDR (rabbit polyclonal, Cell Signal-
ing Technology). Alexa-Fluor 488- or 594-conjugated secondary 
antibodies specific to the appropriate species were used to detect 
bound primary antibodies (Molecular Probes, 1:500). Nuclei were 
counterstained with DAPI (Sigma). Images were captured using a 
DMI6000-AF6000 Leica microscopic imaging system.
In vitro vascular tube formation assay
50 µl Matrigel per well was placed into wells of a 96-well plate 
and incubated at 37 °C for 1 h. 1.5 × 10
4 of either hPSC-derived 
endothelial lineage cells sorted by FACS, HUVECs (Cell Ap-
plications Inc) or HUCBCs (Harvard University) were suspended 
in 100 µl of EBM-2 supplemented with 5% FBS and 50 ng/ml 
VEGF, and then seeded onto the Matrigel plugs. After 12 h to 24 
h, the endothelial lineage cells formed vascular network on the 
plugs, which was visualized by phase-contrast microscopy. EGFP-
negative cells were stained with fluorescent calcein AM (BD Bio-
science). Using a fluorescence microscope (Leica), images in four 
random fields per well were obtained and processed to measure 
the vascular length and area quantitatively using imaging analysis 
software (Image J, NIH). Data was averaged per high-power field. 
All experiments were performed in quadruplicate.
Cell proliferation assay
Cell proliferative activity was measured using 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2H-tetrazolium inner 
salt (MTS; Promega). The sorted endothelial lineage cells were 
seeded on 96-well plates in 100 µl of EBM-2 containing 2% FBS 
with 50 ng/ml VEGF. At each time point, 20 μl of the MTS solu-
tion per well was added. After incubation at 37 °C with 5% CO2 
for 1 h, the absorbance at 490 nm, which is known to correlate 
with the cell number in the assay [68], was recorded using an 
ELISA 96-well plate reader. All experiments were performed in 
quadruplicate.
Quantitative RT-PCR
Total RNA was isolated from the cells cultured or sorted by 
FACS using RNeasy mini extraction kit (Qiagen) and reverse-tran-
scribed to cDNA using the iScript cDNA synthesis kit (Bio-Rad). 
Quantitative real-time RT-PCR was performed on a MasterCycler 
EP Realplex (Eppendorf) using HotStart-IT SYBR Green Master 
Mix (Affymetrix) for 40 cycles. Standard deviations of the means 
in quantitative RT-PCR experiments were obtained from three Formation of human PSC-derived endothelial progenitors
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independent experiments. Primer sequences are listed in Supple-
mentary information, Table S3. Threshold cycles of primer probes 
were normalized to the housekeeping gene GAPDH and translated 
to relative values.
Gene expression analysis for sorted cell populations
Human angiogenesis PCR arrays (SABioscieneces) were used 
to examine the expression profiles of angiogenic genes in the 
sorted cell populations. Using RNeasy mini extraction kit (Qia-
gen), total RNA was extracted from hESC-derived EC subpopula-
tions sorted by FACS, including CD34
+CD14
−, CD34
−CD14
−, and 
CD14
+ cells among VEC
+CD31
+ ECs, VEC
−CD31
− cells (non-ECs), 
HUVECs, and HUCBCs, respectively. Clustergram construction 
and analysis of quantitative PCR data were conducted according to 
the manufacturer’s instructions.
Single-cell clonal assays
Single cells from subpopulations of hVEC-EGFP hESC-derived 
endothelial lineages (CD34
+CD14
−, CD34
−CD14
− or CD14
+ ECs) 
were seeded out in a well of a 96-well flat-bottom tissue culture 
plate precoated with fibronectin using a FACSAria cell sorter (BD 
Biosciences), and cultured in 200 µl EBM-2 media with 2% FBS 
and 50 ng/ml VEGF. To ensure that only one cell had been placed 
into each well, individual wells were examined under a fluores-
cence microscope. Cells were then cultured at 37 °C with 5% CO2, 
and media was changed every 3 days. On day 14, each well was 
examined for the growth of ECs. Wells where two or more ECs 
were detected using a fluorescence microscope were judged as 
positive. The number of cells per well was determined by manual 
inspection using a fluorescence microscope at 100× magnification. 
In wells containing more than 100 cells, quantification was per-
formed through trypsinization and manual counting using a hema-
cytometer. 
Western blot
Total cellular protein was extracted from cultured cells after 
homogenization in a LP40 lysis buffer containing protease inhibi-
tor and phosphatase inhibitor cocktails (both from Roche). Nuclear 
protein from cultured cells was obtained through the ProteoExtract 
Subcellular Proteome Extraction kit (EMD). Protein samples (5 
µg) of nuclear extraction or total lysates were separated by SDS-
PAGE and transferred onto nitrocellulose membranes (Bio-Rad). 
Membranes were incubated with primary antibodies to human 
activated Notch1 (Notch1 intracellular domain) and Dll4 (Abcam), 
followed by incubation with horseradish peroxidase-conjugated 
secondary antibodies (Dako) specific to the appropriate species. 
Enhanced chemiluminescent (ECL) substrate (SuperSignal West 
Femto Substrate; Thermo Scientific) was used to detect bound an-
tibody. Bands were visualized onto autoradiography films, scanned 
and quantified with Image J. The signal intensity was normalized 
to β-actin expression.
Knockdown studies
The shRNA lentiviral constructs targeting Notch1, RBP-Jκ, 
Hes1, and Hey1, as well as the control non-targeting shRNA con-
struct, were all obtained from Open Biosystems and subcloned into 
the pTRIPZ-based lentiviral vector system. Tetracycline-inducible 
lentiviral particles were assembled by transfecting these shRNA 
vectors into 293FT cells along with packaging vectors and used to 
transduce undifferentiated hVEC-EGFP hESCs. After selection by 
antibiotic resistance, the transduced hESCs were picked for isola-
tion and expanded. These tetracycline-inducible shRNA hESC 
lines were then differentiated into endothelial lineages using pro-
tocols described above. To obtain the time-dependent knockdown 
effects for the expression of Notch1, RBP-Jκ, Hes1, or Hey1, 1 
µg/ml doxycycline (Sigma) was added to the culture medium at 
the indicated time point.
Plasmid constructs and dual luciferace assay
A 1.2-kilobase fragment (−900, +296) of the human KDR pro-
moter region [23] was isolated and amplified from a BAC clone by 
PCR. The fragment was placed upstream of the firefly luciferase 
gene in the pGL3 basic plasmid (Promega). The resulting reporter 
plasmid (pKDR-Luc) was transiently transfected with a control 
vector (pRL-SV40; Promega) into undifferentiated hESCs using 
Fugene HD Transfection Reagent (Roche). After 6 h, pKDR-Luc-
transfected hESCs were stimulated with BMP4 with or without a 
GSK-3β inhibitor for the next 12 h. After 18 h, luciferase activi-
ties were measured using a luminometer (Berthold technologies). 
Cells were thereafter treated with VEGF-A with or without rhDll4 
or DAPT for additional 18 h. Thirty-six hours after the initial 
transfection, luciferase activities were measured. Firefly luciferase 
activity was normalized to control Renilla luciferase.
Isolation and culturing of human fetal heart-derived CMCs
Human fetal hearts at 9 weeks of gestation were obtained from 
authorized sources. Hearts were cut in small pieces, washed re-
petitively in solution A (10 mM HEPES, 35 mM NaCl, 10 mM 
glucose, 134 mM sucrose, 16 mM Na2HPO4, 25 mM NaHCO3, 7.75 
mM KCl, and 1.18 mM KH2PO4, pH 7.4). The first digestion step 
was performed in solution A supplemented with 0.5% BSA, 200 
U/ml collagenase type II (Worthington), and 6 U/ml protease type 
XXIV (Sigma) at 37 °C for 20 min to remove red blood cells and 
cell debris. This was followed by four digestion steps performed in 
solution A supplemented with 400 U/ml collagenase type II at 37 
°C for 20 min and centrifuged at 30× g for 1 min, to separate the 
CMC fraction containing KDR
+ precursors from mature cardio-
myocytes [45]. The supernatant containing the CMC fraction was 
collected, neutralized with FBS, and centrifuged at 1 200 rpm for 
5 min. The CMC pellet was resuspended in DMEM (high glucose) 
supplemented with 2 mM L-glutamine, 25 mM HEPES, 10% 
newborn calf serum, 5% FBS, and 1% pen/strep and cultured on 
Matrigel-coated 6-well plates with or without DAPT for 4-6 days 
prior to immunostaining and FACS analyses for the detection of 
KDR.
In vivo Matrigel plug study
All experimental procedures and protocols involving animals 
were approved by the Institutional Animal Care and Use Commit-
tee (IACUC) and the IRB for human and animal research at MGH 
and complied with the Guide for the Care and Use of Laboratory 
Animals (National Institutes of Health (NIH) publication no. 86-
23; revised 1985).
To assess the angiogenic potency of the hVEC-EGFP hESC-
derived endothelial lineage cells to form functionally grafted vas-
culature in vivo, 1-10 × 10
6 of sorted EPs (day 6) and ECs (day 14) 
were suspended in a Matrigel solution containing 400 µl Matrigel 
and 100 µl EBM-2 supplemented with 10% FBS and 100 ng/ml www.cell-research.com | Cell Research
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VEGF and injected subcutaneously into the back of immunocom-
promised mice (NOD/SCID; NCI-Frederick). As a control experi-
ment, the same number of VEC-EGFP
+ HUVECs with Matrigel 
was injected into the NOD/SCID mice as well. After 2 weeks, 
the implanted Matrigel plugs were observed in live mice using a 
fluorescence microscope (Leica), and images in four random fields 
per plug were obtained and processed to measure the vascular 
length and area quantitatively using Image J. At the designated 
time points (2-12 weeks after implantation), the Matrigel plugs are 
harvested for histological analyses. Separately, we administered 
intra-vitally isolectin GS-IB4 from Griffonia simplicifolia (Life 
Technologies) into a subset of the plug-implanted mice through 
intravenous injection, followed by the harvest of the plugs for his-
tological analyses as well. 
Fluorescent Immunohistochemistry
The harvested Matrigel plugs were fixed in 4% paraformalde-
hyde, processed through a sucrose gradient, and embedded in fro-
zen OCT compound (Tissue Tek). Cryosections (8 µm thick) were 
subjected to double immunofluorescence staining using the fol-
lowing primary antibodies: anti-GFP (rabbit polyclonal, Molecular 
Probes); anti-CD31 (rat monoclonal antibody, BD Bioscience); 
and anti-mouse VEC (rat monoclonal antibody, R&D). Alexa-
Fluor 488- and 594-conjugated secondary antibodies specific to 
the appropriate species were used (Molecular Probes, 1:500). The 
nuclei were counterstained with DAPI (Sigma). 
A subset of the Matrigel plugs were subjected to whole-mount 
immunostaining according to the instructions previously described 
[69]. Briefly, the Matrigel plugs were prefixed in 0.1 M PBS with 
microwave irradiation (600 W, 20 s) and incubated in fixing solu-
tion (2% paraformaldehyde) for 1 h at 4 °C. After washing, im-
munofluorescent staining of the fixed specimens was performed 
as described above. All Images were captured using a DMI6000-
AF6000 Leica microscopic imaging system.
Experimental MI model 
MI was induced in 8-10-week NOD/SCID mice by permanent 
ligation of the LAD, as previously described [70]. Briefly, mice 
were anesthetized by intraperitoneal injection of ketamine (80 
mg/kg of body weight) combined with xylazine hydrochloride 
(16 mg/kg of body weight). After intubation and under mechani-
cal ventilation (MouseVent G500; Kent Scientific Corp.), the 
heart was exposed through a left thoracotomy, and a suture was 
placed to ligate the LAD. Immediately after ligation, a total of 
1 × 10
7 hVEC-EGFP hESC-derived EPs in PBS or vehicle (con-
trol) was introduced by direct intramuscular injections into the 
peri-infarcted regions of the myocardium (n = 5, respectively). 
Transthoracic echocardiography (Acuson Sequoia 512 system) 
was performed with a 14-MHz linear transducer before surgery 
and 1 and 28 days after MI. Two-dimensional images and M-mode 
tracings were recorded on the short-axis view at the high papillary 
muscle level. LVEDD and LVESD were measured for more than 
10 beats in a blind fashion. For the assessment of LV function, FS 
was calculated as follows: (LVEDD − LVESD)/LVEDD × 100 (%). 
Twenty-eight days after MI, the hearts were harvested and fixed in 
4% paraformaldehyde for cryosectioning and immunostaining, as 
described above. 
Separately, survival analysis was performed, and the mice 
injected with 1 × 10
7 EPs or vehicle were followed up to 45 days 
after MI (n = 14, respectively).
Statistical analysis
Data are presented as mean ± SD. Differences between groups 
was examined for statistical significance using Student’s t-test or 
one-way ANOVA followed by Tukey-Kramer post-hoc test. The 
survival curves in a MI model were analyzed by the Kaplan-Meier 
method and compared using the log-rank test. Statistical signifi-
cance is defined as P < 0.05.
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